Beacon RNA Cited in Nature’s NPJ Genomic Medicine Journal

Beacon RNA, a leading RNA therapeutics database, has been cited in a recent publication by Jones et al, titled “Breaking the mold with RNA—a “RNAissance” of life science“, in Nature’s NPJ Genomic Medicine Journal (DOI: 10.1038/s41525-023-00387-4). The study highlights the role Beacon RNA can play in advancing RNA-based research, underscoring its value in precision medicine and genetic investigations.

The publication provides an in-depth analysis of RNA drug development, highlighting the expansion of various RNA classes and the rapid growth of the mRNA pipeline across multiple therapeutic areas. A key part of the study was supported by data obtained from Beacon Intelligence, which provided insights into the number of programs by RNA class and the therapeutic distribution of the mRNA pipeline.

RNA therapeutics have emerged as one of the most promising areas in modern medicine, with applications spanning oncology, rare diseases, infectious diseases, and more. The rise of mRNA-based treatments, particularly in response to the COVID-19 pandemic, has demonstrated the immense potential of RNA platforms to address a wide range of medical conditions.

The Nature article emphasizes the importance of accurate and comprehensive data in tracking and analyzing the evolution of these therapies, a gap that Beacon RNA fills with its industry-leading intelligence platform. Beacon Intelligence supplied this exclusive data through its RNA dataset using the ‘Drug Data’ view.

Ioana Panait, Senior Lead Research Analyst, at Beacon Intelligence comments: “Being cited in Nature highlights the value and impact of Beacon’s comprehensive RNA dataset. Researchers and industry leaders rely on our data to navigate the complexities of RNA therapeutics, accelerating the development of ground-breaking treatments. This acknowledgment reinforces our commitment to providing industry-leading intelligence for the scientific community.”

Beacon Intelligence’s RNA dataset is meticulously curated by a team of expert analysts who continuously monitor industry developments, clinical trials, and emerging trends in RNA-based drug development. This ensures that subscribers to Beacon RNA have access to the latest intelligence, enabling them to make informed strategic decisions in drug discovery and development.

In addition to RNA therapeutics, Beacon Intelligence provides datasets covering a broad spectrum of complex drug modalities, including Antibody Drug-Conjugates (ADCs), Cell Therapies, Gene Therapies and Bispecifics. This comprehensive approach positions Beacon Intelligence as a key resource for biotech and pharmaceutical companies, investors, and researchers seeking to understand the evolving drug development landscape.

The citation in Nature further solidifies Beacon RNA’s reputation as a trusted source of high-quality intelligence. By offering granular data on RNA therapeutic development, including pipeline distribution, preclinical and clinical trial progress, and competitive intelligence, Beacon Intelligence plays a vital role in supporting innovation and accelerating the translation of RNA research into real-world treatments.

What is Beacon RNA?

Beacon RNA is the most comprehensive RNA therapeutics database available. Providing timely and accurate, market leading, pre-clinical and clinical RNA drug, trial, and commercial intelligence data.

  • Unrivalled comprehensive & accurate pre-clinical and clinical RNA therapeutic drug, trial and commercial data.
  • Access to >4,500 Drugs, >2,000 Trials, >2,500 Companies, and >2,500 Deals in the RNA Therapeutic space
  • Market leading ontologies, enabling precise navigation of specific RNA therapeutics
  • Manually curated by RNA scientists, with data updated daily
  • Your one stop shop for RNA therapeutic intelligence data

Learn More About Beacon RNA